Janux Therapeutics (JANX) Accumulated Expenses (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Accumulated Expenses data on file, last reported at $12.4 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $12.4 million, down 7.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.4 million (down 7.14% YoY), and the FY2025 annual result was $4.6 million, down 25.97% from the prior year.
• Accumulated Expenses advanced to $12.4 million in Q1 2026 per JANX's latest filing, from $4.6 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $17.6 million in Q3 2025 and troughed at $1.2 million in Q2 2022.
• A 5-year average of $7.0 million and a median of $6.2 million in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses surged 598.46% in 2022, then sank 60.42% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $8.2 million in 2022, then slumped by 56.78% to $3.5 million in 2023, then jumped by 75.39% to $6.2 million in 2024, then slipped by 25.97% to $4.6 million in 2025, then surged by 169.87% to $12.4 million in 2026.
• Business Quant data shows JANX's Accumulated Expenses at $12.4 million in Q1 2026, $4.6 million in Q4 2025, and $17.6 million in Q3 2025.